• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 3. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Phenylpyrazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Phenylpyrazoles

Introduction to 4-(4-Methyl-1H-pyrazol-1-yl)benzonitrile (CAS No. 873009-49-5)

4-(4-Methyl-1H-pyrazol-1-yl)benzonitrile, with the chemical formula C₁₁H₁₀N₂, is a significant compound in the field of pharmaceutical and medicinal chemistry. This heterocyclic aromatic nitrile derivative has garnered considerable attention due to its unique structural properties and potential applications in drug development. The compound's molecular structure incorporates both a pyrazole ring and a benzonitrile moiety, which are known for their diverse biological activities. In this comprehensive overview, we will delve into the chemical characteristics, synthetic pathways, and recent advancements in the research and application of this compound.

The CAS number 873009-49-5 uniquely identifies this compound in scientific literature and databases, ensuring precise classification and reference. The presence of a 4-methyl-1H-pyrazol-1-yl substituent in the benzene ring introduces a tunable electronic and steric environment, making it a versatile scaffold for medicinal chemistry modifications. This feature allows researchers to fine-tune the pharmacokinetic and pharmacodynamic properties of derivatives derived from this core structure.

Benzonitrile derivatives are widely recognized for their role as intermediates in the synthesis of various bioactive molecules. The nitrile group (-CN) in 4-(4-methyl-1H-pyrazol-1-yl)benzonitrile contributes to its reactivity, enabling further functionalization through hydrolysis, reduction, or coupling reactions. These transformations are pivotal in generating novel compounds with enhanced therapeutic potential.

Recent studies have highlighted the pharmacological significance of pyrazole-containing compounds. Pyrazoles are known for their anti-inflammatory, antimicrobial, and anticancer properties. The integration of a pyrazole ring with a benzonitrile moiety in 4-(4-methyl-1H-pyrazol-1-yl)benzonitrile creates a promising platform for designing drugs that target multiple disease pathways simultaneously. This dual functionality has been explored in preclinical studies aiming to develop treatments for complex diseases such as cancer and neurodegenerative disorders.

In terms of synthetic methodologies, the preparation of 4-(4-methyl-1H-pyrazol-1-yl)benzonitrile involves multi-step organic synthesis. One common approach includes the condensation of 4-methylpyrazole with appropriate benzene derivatives under controlled conditions. Advanced techniques such as palladium-catalyzed cross-coupling reactions have also been employed to achieve higher yields and purities. These synthetic strategies are crucial for producing sufficient quantities of the compound for both research and commercial purposes.

The biological activity of 4-(4-methyl-1H-pyrazol-1-yl)benzonitrile has been extensively investigated in recent years. Researchers have demonstrated its potential as an inhibitor of various enzymes and receptors implicated in diseases like cancer and inflammation. For instance, derivatives of this compound have shown inhibitory effects on kinases and proteases that play critical roles in tumor progression. Additionally, its interaction with specific biological targets has been studied to understand its mechanism of action at the molecular level.

The structure-activity relationship (SAR) analysis of 4-(4-methyl-1H-pyrazol-1-yl)benzonitrile has provided valuable insights into optimizing its pharmacological properties. By modifying substituents on the pyrazole or benzene ring, researchers can enhance binding affinity, metabolic stability, and overall efficacy. These findings are instrumental in guiding the design of next-generation drugs with improved therapeutic profiles.

Advances in computational chemistry have further accelerated the discovery process for compounds like 4-(4-methyl-1H-pyrazol-1-yl)benzonitrile. Molecular modeling techniques allow scientists to predict the binding modes of this compound with biological targets, thereby facilitating rational drug design. Such computational approaches complement experimental efforts by providing rapid screening of potential derivatives before synthesizing them in the lab.

The pharmaceutical industry has shown interest in leveraging the unique properties of 4-(4-methyl-1H-pyrazol-1-yl)benzonitrile for developing new treatments. Collaborative efforts between academic institutions and pharmaceutical companies have led to several patents and clinical trials exploring its therapeutic applications. These initiatives underscore the compound's potential as a lead molecule for innovative drug development programs.

In conclusion, 4-(4-methyl-1H-pyrazol-1-yl)benzonitrile (CAS No. 873009-49-5) represents a significant advancement in medicinal chemistry due to its versatile structure and promising biological activities. Ongoing research continues to uncover new applications for this compound, reinforcing its importance in addressing unmet medical needs. As our understanding of its pharmacological properties deepens, so does its potential to contribute to next-generation therapeutics.

• 25775-03-5(2-(1H-Pyrazol-1-yl)benzonitrile)
• 712-39-0(1-(o-Tolyl)-1H-pyrazole-4-carbonitrile)
• 25699-83-6(4-(1H-Pyrazol-1-yl)benzonitrile)
• 712-72-1(1-(p-Tolyl)-1H-pyrazole-4-carbonitrile)
• 25699-82-5(3-(1H-Pyrazol-1-yl)benzonitrile)
• 14766-43-9(1-Phenyl-4-methylpyrazole)
• 1015862-36-8(1-(4-Fluorophenyl)-1H-pyrazole-4-carbonitrile)
• 709-04-6(1-Phenyl-1H-pyrazole-4-carbonitrile)
• 400876-79-1((1-p-Tolyl-1H-pyrazol-4-yl)methanamine)
• 82525-28-8(1H-Pyrazole, 4-(4-methylphenyl)-1-phenyl-)